Posted: November 12, 2025
Explore Assays from DiaPharma to Enhance Your Anticoagulation Research FXIa Research Assays from DiaPharma DAPTTIN® TC Reagent* Thrombin Generation Assays* Chromogenic Substrates and Reagents* DOAC-STOP™ Tablets* * For research use only. Not for use in diagnostic procedures. ML-00-01251 Rev 01
Posted: November 12, 2025
Introducing Pplus Platelet Products! Pplus Medical Limited is a MedTech company located in Ireland, specializing in regenerative medicine, using advanced Platelet Rich Plasma (PRP) technology to drive innovation in personalized care. Pplus Digital Storage Device (DSD™)* Revolutionizing Platelet Storage Wherever You Need It DSD™ Transport Bag* Pplus Sterile Ampoules* Collagen-Related Peptide-A (CRP-A™)* We would be…
Posted: November 12, 2025
From basic fibrinolysis research to translational research surrounding thrombolytics, you need reliable, relevant tests. DiaPharma has you covered. Featured Products TECHNOZYM® PAI-1 ACTIBIND® ELISA* Technozym® PAP Complex ELISA* Automated Plasmin Generation Assay (PAG)* Chromogenic Substrate Assays *For research use only in US and Canada. Not for use in diagnostic procedures.
Posted: October 30, 2025
Contributed by Abigail Kasberg, PhD Hepatitis B is a viral infection that is caused by the Hepatitis B virus (HBV). Infection with HBV primarily affects the liver, driving acute and chronic liver disease. Long-term HBV infection can lead to cirrhosis, liver failure, and hepatocellular carcinoma (HCC) (Figure 1). HBV infection is the leading cause of…
Posted: October 29, 2025
Contributed by Abigail Kasberg, PhD Alcohol-related clinical trials play a fundamental role in advancing our understanding of the complex impact of alcohol consumption on human health. The prevalence of alcohol use is widespread, causing a systemic impact on the individual and affecting whole communities. Clinical trials are a means to investigate the mechanisms of alcohol-related…
Posted: June 27, 2025
See what we unveiled at ISTH 2025! VIEW VIDEO We are grateful for the opportunity to connect and discuss the latest advancements for the hemostasis laboratory at ISTH 2025. The science and collaboration were outstanding. Many thanks to all who worked so hard to make it a success! DiaPharma was proud to highlight: CLINICAL &…
Posted: April 11, 2025
David L. McGlasson, MS, MLS(ASCP) A recent episode of “Differential Discussions” digs into the utility of the chromogenic factor X (CFX) assay for monitoring patients on oral anticoagulant therapy (OAT). Data from previous studies and a case study were discussed. A study was presented that compared International Normalized Ratio (INR) values with CFX results, to…
Posted: March 31, 2025
— Contributed by Olivia Stricker, PhD and Jessica Tuohy, PhD The 2025 AASLD Emerging Topics Conference in Las Vegas delivered an invigorating discussion on one of the most pressing challenges in hepatology today—metabolic dysfunction-associated alcohol-related liver disease (metALD) and the evolving landscape of ALD clinical trials. As research advances, our understanding of these diseases continues…
Posted: December 10, 2024
-Contributed by Abi Kasberg, PhD Immunothrombosis defines the delicate intersection of innate immunity and coagulation. This complex bidirectional interaction between the immune system and clotting components activate each other, leading to abnormal clotting events when unbalanced. A central component to immunothrombosis is the NETosis response of activated neutrophils that result in the expulsion of neutrophil…
Posted: December 10, 2024
-Contributed by Olivia Stricker, PhD and Abi Kasberg, PhD The relationship between metabolic disorders and liver disease is striking. Liver disease affects 75% of individuals with type 2 diabetes (T2D), making metabolic disorders the most common underlying cause of liver disease in the U.S (Gobejishvili et al. 2024). The liver diseases associated with T2D range…